Joël Jean-Louis Besse
Plus aucun poste en cours
Profil
Joël Jean-Louis Besse is currently the Chief Executive Officer at Pharma Group Santé SAS and the Director at U3 Pharma AG since 2009.
Previously, he served as the Chairman at NFL Biosciences SAS from 2018 to 2023.
He has also held director positions at various companies including Prestwick Pharmaceuticals, Inc., FIBREX Medical, Inc., Xytis, Inc., Novuspharma SpA, Arrow Therapeutics Ltd., Immuno-Designed Molecules SA, Neurotech Pharmaceuticals, Inc. (United States), Novexel SA, Newron Pharmaceuticals SpA, Actelion Pharmaceuticals UK Ltd., Entomed SA, Arthur Andersen LLP, Atlas Venture LLP, Axovan AG, and Horizon Therapeutics Switzerland GmbH.
Mr. Besse completed his undergraduate studies at Université Fédérale Toulouse Midi-Pyrénées and École Nationale Supérieure de Aéronautique et de l’Espace.
Postes actifs de Joël Jean-Louis Besse
| Sociétés | Poste | Début |
|---|---|---|
U3 Pharma AG
 U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Directeur/Membre du Conseil | - |
Anciens postes connus de Joël Jean-Louis Besse
| Sociétés | Poste | Fin |
|---|---|---|
| NFL BIOSCIENCES | Président | 27/02/2023 |
FIBREX Medical, Inc.
 FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Directeur/Membre du Conseil | 05/02/2013 |
| NEWRON PHARMACEUTICALS S.P.A. | Directeur/Membre du Conseil | 17/11/2006 |
| Novuspharma SpA | Directeur/Membre du Conseil | 01/01/2004 |
Neurotech Pharmaceuticals, Inc. (United States)
 Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Directeur/Membre du Conseil | - |
Formation de Joël Jean-Louis Besse
| École Nationale Supérieure de Aéronautique et de l’Espace | Undergraduate Degree |
| Université Fédérale Toulouse Midi-Pyrénées | Undergraduate Degree |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| NEWRON PHARMACEUTICALS S.P.A. | Health Technology |
| NFL BIOSCIENCES | Health Technology |
| Entreprise privées | 15 |
|---|---|
Prestwick Pharmaceuticals, Inc.
 Prestwick Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Prestwick Pharmaceuticals, Inc. develops drugs for diseases related to the central nervous system. Its drugs are used in curing diseases such as Huntington's, Parkinson's, restless legs syndrome, schizophrenia, autism, Alzheimer's, and sleep apnea diseases. The company was founded in 2002 and is headquartered in Washington DC. | Health Technology |
FIBREX Medical, Inc.
FIBREX Medical, Inc. Miscellaneous Commercial ServicesCommercial Services FIBREX Medical Inc. is a development stage bio-pharmaceutical company. Its operational affiliate FIBREX Medical Research & Development GmbH was established in Vienna in February 2001. The company was founded to convert high impact scientific discovery into pharmaceutical products for important diseases. The company aims to become a leader in the development and commercialization of pharmaceuticals targeting fundamental mechanisms of inflammation and tissue injury. While inflammation is highly desirable to defend the organism against foreign particles and infections, it can become harmful and destructive if it runs unchecked. Inflammation-based tissue injury is well known as a major component in the pathogenesis and progression of important diseases such as myocardial infarction, septic and hemorrhagic shock, graft rejection, or rheumatoid arthritis. In addition, endothelial dysfunction in inflamed tissues leads to capillary leak and deleterious edema formation, aggravating organ dysfunction. | Commercial Services |
Xytis, Inc.
 Xytis, Inc. BiotechnologyHealth Technology Xytis, Inc. was engaged in the development of central nervous system. The company was founded by Werner Tschollar in January 2006 and was headquartered in Irvine, CA. | Health Technology |
| Novuspharma SpA | Health Technology |
Arthur Andersen LLP
 Arthur Andersen LLP Miscellaneous Commercial ServicesCommercial Services Arthur Andersen LLP used to provide accounting services. It was also into consulting services for clients that operate businesses throughout the United States and around the world. Arthur Andersen was founded in 1913 and was headquartered in Chicago, IL. | Commercial Services |
Arrow Therapeutics Ltd.
 Arrow Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Arrow Therapeutics Ltd. operates as a pharmaceutical company that focuses on research and development of novel antiviral drugs. Its products include novel antibacterial, antiviral, antifungal and preclinical compounds. The company was founded in 1998 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
| Immuno-Designed Molecules SA | Health Technology |
Atlas Venture LLP
 Atlas Venture LLP Investment ManagersFinance Atlas Venture LLP is the London office of the independent and partner-owned venture capital investment group Atlas Venture Inc., headquartered in Boston with additional offices in Paris and Munich, plus an administrative office in Amsterdam. The group originated in 1980 and focuses on high-technology financing, aiming for a transatlantic operations model. The London office was established in 1986. The group manages a range of venture capital funds. | Finance |
Neurotech Pharmaceuticals, Inc. (United States)
Neurotech Pharmaceuticals, Inc. (United States) Pharmaceuticals: MajorHealth Technology Neurotech Pharmaceuticals, Inc. designs and develops therapeutic systems for retinal diseases. The company was founded in 1995 and is headquartered in Cumberland, RI. | Health Technology |
U3 Pharma AG
U3 Pharma AG Miscellaneous Commercial ServicesCommercial Services U3 Pharma AG researches and develops novel targeted therapeutics aimed at treating human disease. It develops products for hyperproliferative diseases such as cancer and commercializes human monoclonal antibody therapies directed against validated proprietary drug targets selected from its portfolio. In addition, it has created a second generation functional genomics platform, TASC, which mimics the progression of a tumor cell as it progresses towards its fully malignant cancerous state. Founded in 2001, the company is headquartered in Martinsried, Germany. | Commercial Services |
Horizon Therapeutics Switzerland GmbH
 Horizon Therapeutics Switzerland GmbH Pharmaceuticals: MajorHealth Technology Horizon Therapeutics Schweiz GmbH is a biopharmaceutical company that develops and commercializes medicines to target unmet therapeutic needs in arthritis, pain and inflammatory diseases. The company was originally founded in 2004 as a spin-out of Merck KGaA and is headquartered in Reinach, Switzerland. | Health Technology |
Novexel SA
 Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Actelion Pharmaceuticals UK Ltd.
 Actelion Pharmaceuticals UK Ltd. Medical DistributorsDistribution Services Actelion Pharmaceuticals UK Ltd. discovers, develops, and markets drugs. Its products are Tracleer for the treatment of pulmonary arterial hypertension and Zavesca, which is used to treat Type 1 Gaucher disease. The company is headquartered in London, UK. | Distribution Services |
Axovan AG
 Axovan AG Miscellaneous Commercial ServicesCommercial Services Axovan AG conducts biopharmaceutical research and develops pharmaceuticals. Active in pharmaceutical research and development, it focuses on the family of drug targets called G protein-coupled receptors (GPCRs), which are involved in a number of pathologies. It has developed a validated GPCR-based chemical library through its proprietary chem-informatics platform AXADDIS. Its lead product, clasozentan, is an intravenous endothelin receptor antagonist optimized for treating cerebral diseases. It is partnering non-core indication projects (pain, metabolic diseases, inflammation) at earlier stages. The company was founded in 2000 and is headquartered in Allschwil, Switzerland. | Commercial Services |
Entomed SA
 Entomed SA Pharmaceuticals: MajorHealth Technology Entomed SA discovers and develops novel medicines derived from insects. It discovers and develops new drugs derived from the biology of insects with a focus on their immune response. Entomed's technology is based on the scientific work carried out by Prof. Jules A. Hoffmann's world leading team in the CNRS Institute of Molecular and Cellular Biology (IBMC) in Strasbourg. The company was founded in 1999 and is headquartered in Illkirch-Graffenstaden, France. | Health Technology |